Propel Bio Management is an investment fund managing more than $154 billion ran by Jim Harding. There are currently 24 companies in Mr. Harding’s portfolio. The largest investments include Applied Therapeutics and Plains Gp Holdings Lp-cl, together worth $56.5 billion.
As of 5th August 2024, Propel Bio Management’s top holding is 6,567,858 shares of Applied Therapeutics currently worth over $30.7 billion and making up 19.9% of the portfolio value.
Relative to the number of outstanding shares of Applied Therapeutics, Propel Bio Management owns more than 0.1% of the company.
In addition, the fund holds 1,372,360 shares of Plains Gp Holdings Lp-cl worth $25.8 billion.
The third-largest holding is Tscan Therapeutics Inc worth $12.2 billion and the next is Madrigal Pharmaceuticals Inc worth $12.1 billion, with 43,032 shares owned.
Currently, Propel Bio Management's portfolio is worth at least $154 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Propel Bio Management office and employees reside in Los Angeles, California. According to the last 13-F report filed with the SEC, Jim Harding serves as the Finance Director at Propel Bio Management.
In the most recent 13F filing, Propel Bio Management revealed that it had opened a new position in
Plains Gp Holdings Lp-cl and bought 1,372,360 shares worth $25.8 billion.
The investment fund also strengthened its position in Applied Therapeutics by buying
455,952 additional shares.
This makes their stake in Applied Therapeutics total 6,567,858 shares worth $30.7 billion.
Applied Therapeutics dropped approximately 0.1% in the past year.
On the other hand, there are companies that Propel Bio Management is getting rid of from its portfolio.
Propel Bio Management closed its position in Plains Gp Holdings Lp-cl on 12th August 2024.
It sold the previously owned 1,492,581 shares for $28 billion.
The two most similar investment funds to Propel Bio Management are Marvin & Palmer Associates Inc and Alibaba Ltd. They manage $154 billion and $154 billion respectively.
Propel Bio Management’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 62.9% of
the total portfolio value.
The fund focuses on investments in the United States as
54.2% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
21% of the total holdings value.
On the other hand, large-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $628 million.
These positions were updated on August 12th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Applied Therapeutics, Inc. |
7.46%
6,567,858
|
$30,671,897,000 | 19.89% |
| Plains Gp Holdings Lp-cl |
Closed
1,492,581
|
$27,978,962,000 | |
| Plains Gp Holdings Lp-cl |
Opened
1,372,360
|
$25,827,815,000 | 16.75% |
| Tscan Therapeutics Inc |
No change
2,087,139
|
$12,209,763,000 | 7.92% |
| Madrigal Pharmaceuticals Inc |
No change
43,032
|
$12,055,845,000 | 7.82% |
| Achieve Life Sciences Inc. |
No change
2,453,092
|
$11,529,532,000 | 7.48% |
| Phathom Pharmaceuticals I |
No change
869,927
|
$8,960,248,000 | 5.81% |
| Akero Therapeutics Inc |
No change
327,752
|
$7,689,062,000 | 4.99% |
| Avidity Biosciences, Inc. |
No change
178,500
|
$7,291,725,000 | 4.73% |
| Ardelyx Inc |
55.61%
924,583
|
$6,851,160,000 | 4.44% |
| Abeona Therapeutics Inc |
Opened
1,248,044
|
$5,291,706,000 | 3.43% |
| Fulcrum Therapeutics Inc |
No change
750,000
|
$4,650,000,000 | 3.02% |
| Day One Biopharmaceuticals I |
Closed
270,664
|
$4,471,369,000 | |
| Athira Pharma, Inc. |
No change
1,492,792
|
$3,955,899,000 | 2.57% |
| Telesat Corp |
25.79%
365,781
|
$3,328,607,000 | 2.16% |
| Verrica Pharmaceuticals I |
Opened
424,937
|
$3,097,791,000 | 2.01% |
| Kura Oncology Inc |
No change
130,000
|
$2,676,700,000 | 1.74% |
| iShares MBS ETF |
Closed
22,400
|
$2,070,208,000 | |
| Eiger BioPharmaceuticals Inc |
No change
146,381
|
$1,851,720,000 | 1.20% |
| Mirum Pharmaceuticals Inc |
Closed
70,000
|
$1,758,400,000 | |
| Syndax Pharmaceuticals In |
No change
83,259
|
$1,709,307,000 | 1.11% |
| Kymera Therapeutics, Inc. |
No change
56,359
|
$1,682,316,000 | 1.09% |
| Marinus Pharmaceuticals Inc |
Closed
180,100
|
$1,628,104,000 | |
| Kayne Anderson Energy Inf |
No change
147,033
|
$1,518,851,000 | 0.99% |
| Sutro Biopharma Inc |
Closed
195,000
|
$1,101,750,000 | |
| Trevi Therapeutics, Inc. |
No change
260,000
|
$774,800,000 | 0.50% |
| X4 Pharmaceuticals, Inc. |
Closed
535,000
|
$743,650,000 | |
| Ishares Iboxx Investment |
Closed
4,456
|
$485,348,000 | |
| Fidelity Inv Mmtrsy 1 680 |
49.86%
317,014
|
$317,014,000 | 0.21% |
| Cybin Inc |
No change
850,000
|
$230,350,000 | 0.15% |
| Maat Pharma Saca |
Opened
1,362
|
$9,752,000 | 0.01% |
| Chinook Therapeutics, Inc. |
No change
79,357
|
$9,750,000 | 0.01% |
| No transactions found | |||
| Showing first 500 out of 32 holdings | |||